S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:MNKD

MannKind (MNKD) Stock Forecast, Price & News

$4.03
+0.02 (+0.50%)
(As of 09/26/2023 ET)
Compare
Today's Range
$4.01
▼
$4.15
50-Day Range
$4.01
▼
$5.45
52-Week Range
$2.91
▼
$5.75
Volume
2.74 million shs
Average Volume
2.31 million shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.7% Upside
$7.00 Price Target
Short Interest
Bearish
14.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$171,218 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.07) to $0.14 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

783rd out of 963 stocks

Pharmaceutical Preparations Industry

363rd out of 446 stocks

See Top Rated MarketRank™ Stocks Here

MNKD stock logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MNKD Price History

MNKD Stock News Headlines

September 7, 2023 | markets.businessinsider.com
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
September 5, 2023 | finance.yahoo.com
MannKind Corporation Announces Participation at Upcoming Conferences
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 4, 2023 | thestreet.com
3 Stocks the Market Loves to Hate
August 22, 2023 | finance.yahoo.com
When Will MannKind Corporation (NASDAQ:MNKD) Breakeven?
August 22, 2023 | finance.yahoo.com
3 Biotech Stocks to Sell in August Before They Crash and Burn
August 14, 2023 | msn.com
HC Wainwright & Co. Maintains Mannkind (MNKD) Buy Recommendation
August 9, 2023 | msn.com
Cantor Fitzgerald Maintains Mannkind (MNKD) Overweight Recommendation
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 8, 2023 | finance.yahoo.com
Why MannKind Stock Soared 19% Higher on Tuesday
August 8, 2023 | finance.yahoo.com
Q2 2023 MannKind Corp Earnings Call
August 8, 2023 | seekingalpha.com
MannKind's Robust Patient Demand, Operational Efficiency To Drive Revenue Beyond Q2 2023
August 8, 2023 | washingtonpost.com
MannKind: Q2 Earnings Snapshot
August 8, 2023 | markets.businessinsider.com
MannKind Corp. Q2 Earnings Summary
August 8, 2023 | finance.yahoo.com
MannKind Corporation Reports 2023 Second Quarter Financial Results
August 8, 2023 | finance.yahoo.com
Here's What Key Metrics Tell Us About MannKind (MNKD) Q2 Earnings
August 8, 2023 | finance.yahoo.com
MannKind (MNKD) Q2 2023 Earnings Call Transcript
August 8, 2023 | seekingalpha.com
MannKind Corporation 2023 Q2 - Results - Earnings Call Presentation
August 6, 2023 | finance.yahoo.com
MNKD Aug 2023 4.500 put
August 4, 2023 | benzinga.com
Earnings Preview For MannKind
August 1, 2023 | finance.yahoo.com
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
July 31, 2023 | finance.yahoo.com
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 26, 2023 | seekingalpha.com
MannKind: Impressive Progress, But In Need Of Strengthened Finances
July 23, 2023 | thestreet.com
MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt
July 21, 2023 | finance.yahoo.com
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
July 10, 2023 | markets.businessinsider.com
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
July 5, 2023 | gurufocus.com
Insider Sell: MannKind Corp CEO Michael Castagna Sells 10,000 Shares
See More Headlines
Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
CIK
899460
Web
www.mannkindcorp.com
Phone
(818) 661-5000
Fax
661-775-2081
Employees
391
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+73.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-87,400,000.00
Net Margins
-30.00%
Pretax Margin
-30.00%
Return on Equity
N/A
Return on Assets
-16.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.37
Quick Ratio
2.11

Sales & Book Value

Annual Sales
$99.77 million
Price / Sales
10.84
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.95) per share
Price / Book
-4.24

Miscellaneous

Outstanding Shares
268,360,000
Free Float
257,621,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
1.58

Social Links

Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Michael E. Castagna Pharm.D. (Age 46)
    CEO & Director
    Comp: $1.26M
  • Mr. Steven B. BinderMr. Steven B. Binder (Age 60)
    Chief Financial Officer
    Comp: $800.2k
  • Dr. David B. Thomson (Age 56)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $798.53k
  • Dr. Stuart A. Tross Ph.D. (Age 56)
    Exec. VP and Chief People & Workplace Officer
    Comp: $678.4k
  • Mr. Sanjay Singh M.B.A. (Age 56)
    Exec. VP of Technical Operations
    Comp: $364.53k
  • Ms. Lauren M. Sabella (Age 62)
    Exec. VP & COO
  • Mr. Thomas Hofmann M.D.
    Ph.D., Sr. VP & Chief Scientific Officer
  • Ms. Rosabel Realica Alinaya (Age 62)
    VP of Investor Relations & Treasury
  • Mr. John F. Bedard (Age 73)
    Sr. VP of Worldwide Regulatory Affairs
  • Mr. James Patrick McCauley Jr. (Age 57)
    J.D., M.B.A., Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings or view top-rated stocks.

What is MannKind's stock price forecast for 2023?

3 analysts have issued 12-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.50. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 73.7% from the stock's current price.
View analysts price targets for MNKD or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2023?

MannKind's stock was trading at $5.27 at the beginning of 2023. Since then, MNKD stock has decreased by 23.5% and is now trading at $4.03.
View the best growth stocks for 2023 here.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our MNKD earnings forecast.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04. The biopharmaceutical company had revenue of $48.61 million for the quarter, compared to analysts' expectations of $42.03 million.

What ETFs hold MannKind's stock?

ETFs with the largest weight of MannKind (NASDAQ:MNKD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.67%), State Street Corp (5.71%), Davidson Kempner Capital Management LP (0.00%), Geode Capital Management LLC (1.99%), Northern Trust Corp (0.94%) and Charles Schwab Investment Management Inc. (0.74%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.03.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $1.08 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does MannKind have?

The company employs 391 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -